U.S.S.N.: 09/767370 Group Art Unit: 1643

Amendments to the claims

Please amend claims 52, 56, 59, 63, 67, and 69.
Please cancel claims 53-55 and 64-65
Please add new claims 71-77.

1-51. (Canceled)

52. (Currently Amended) A composition comprising active lymphotoxin- β -receptor immunoglobulin (LT- β -R-Ig) fusion proteins and inactive LT- β -R-Ig fusion proteins, wherein no more than 10% 30% of the LT- β -R-Ig fusion proteins are inactive.

53-55. (Canceled)

- 56. (Currently Amended) The composition of claim 52 any one of claims 52 54, wherein the active LT- β -R-Ig fusion proteins are recognized by a functional specific antibody.
- 57. (**Currently Amended**) The composition of <u>claim 52</u> any one of <u>claims 52</u> 54, wherein the LT-β-R-Ig fusion protein comprises an <u>a human</u> Fc domain.
- 58. **(Previously Presented)** A pharmaceutical composition comprising the composition of claim 57, and a pharmaceutically acceptable carrier.
- 59. (Currently Amended) The composition of claim 52 any one of claims 52 54, wherein the Fc domain is of an IgG1 isotype.
- 62. **(Previously Presented)** A pharmaceutical composition comprising the composition of claim 59, and a pharmaceutically acceptable carrier.
- 63. (**Currently Amended**) A composition comprising active and inactive lymphotoxin-β-receptor immunoglobulin (LT-β-R-Ig) fusion proteins, wherein no more than 10% 30% LT-β-R-Ig fusion proteins are inactive, and wherein the active LT-β-R-Ig fusion proteins are obtained by culturing a mammalian host cell transformed with DNA encoding

U.S.S.N.: 09/767370 Group Art Unit: 1643

the LT- β -R-Ig fusion protein in a culture system having a temperature of about 27° C to <u>less</u> than about 30 35° C

64-66. (Canceled)

- 67. (Currently Amended) The composition of <u>claim 63</u> any one of <u>claims 63 66</u>, wherein the LT-β-R-Ig fusion protein comprises an <u>a human</u> Fc domain.
- 68. **(Previously Presented)** A pharmaceutical composition comprising the composition of claim 67, and a pharmaceutically acceptable carrier.
- 69. **(Previously Presented)** The composition of <u>claim 67</u> any one of <u>claims 63 66</u>, wherein the Fc domain is of an IgG1 isotype.
- 70. **(Previously Presented)** A pharmaceutical composition comprising the composition of claim 69, and a pharmaceutically acceptable carrier.
- 71. (New) The composition of claim 52, wherein the active LT- β -R-Ig fusion proteins are glycosylated.
- 72. **(New)** A composition comprising active lymphotoxin- β -receptor immunoglobulin (LT- β -R-Ig) fusion proteins and inactive LT- β -R-Ig fusion proteins, wherein no more than 6% of the LT- β -R-Ig fusion proteins are inactive.
- 73. (New) The composition of claim 72, wherein the LT- β -R-Ig fusion protein comprises a human Fc domain.
- 74. **(New)** The composition of claim 72, wherein the active lymphotoxin- β -receptor immunoglobulin (LT- β -R-Ig) fusion proteins are glycosylated.
- 75. **(New)** A pharmaceutical composition comprising the composition of claim 72, and a pharmaceutically acceptable carrier.
- 76. (New) The composition of claim 73, wherein the Fc domain is of an IgG1 isotype.

77. **(New)** A pharmaceutical composition comprising the composition of claim 76, and a pharmaceutically acceptable carrier.